PRNewsWire
21 May 2026, 19:45 UTC · 17w ago
Verdict
Headline takes no side. We score RPD −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Pomerantz LLP is investigating Sanara MedTech (SMTI) for potential securities fraud or unlawful business practices.
More negative than 92% of claims this week
Sanara MedTech discontinued operations of its Tissue Health Plus (THP) program.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 81% of claims this week
Sanara reported a $31.2 million net loss from discontinued operations, including a $26.5 million noncash asset impairment charge.
More negative than 73% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is being investigated by a law firm for claims on behalf of investors.
More negative than 96% of ticker scores this week
The company is being investigated by a law firm for claims on behalf of investors.
More negative than 96% of ticker scores this week
The company is the subject of a securities fraud investigation following a massive net loss and a significant stock price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
+63.7%
Price is moving against the score
$11.97 vs $7.31 close before publication (May 20) · not market-adjusted
RPD chart →
